To determine the cost-effectiveness of interventions for major depression in Thailand. METHODS: A microsimulation model was developed to describe the course of disease in individuals. Model inputs included Thai data on disease parameters and costs while impact measures are derived from a systematic review and meta-analysis of the international literature. Results are presented as cost (Thai Baht) per disability adjusted life-year (DALY) averted, compared to the null scenario (do nothing). Fluoxetine as the cheapest antidepressant drug in Thailand was analyzed for treatment of episodes plus a 6 month continuation phase and for maintenance treatment over 5 years of follow-up. Cognitive behavioral therapy (CBT) was analyzed for episodic treatment and for 5-year maintenance treatment. RESULTS: The incremental cost-effectiveness ratios (ICER) of fl uoxetine for episodic treatment with or without a continuation or maintenance phase are just below one times GDP per capita in Thailand of 110,000 Baht. CBT during an episode of depression (ICER = 39,000) is more costeffective than medications (ICER = 88,000); a maintenance version of CBT is the most cost-effective option with an ICER of 27,000. Episodic drug treatment has the lowest cost (250 Million Baht) and averts 3000 DALYs. Episodic treatment with CBT, which has an ongoing effect for 1.5 years, costs 100 Million Baht more than drug treatment but it averts more than 6000 DALYs compared to drugs. CONCLUSIONS: CBT is the most cost-effective treatment option for both episodic and maintenance treatment. Maintenance treatment is the more cost-effective of the two. However, there is currently a lack of mental health personal, especially psychiatrists and psychologists, who would be expected to deliver CBT in Thailand. Antidepressant drugs are quite a bit less effective but also less costly than CBT. OBJECTIVES: To determine the optimal treatment package, including drug and non drug interventions, for schizophrenia in Thailand. METHODS: A Markov model was used to evaluate the cost-effectiveness of typical antipsychotics, generic risperidone, olanzapine, clozapine and family interventions. Health outcomes were measured in disability adjusted life-years. We considered health outcomes from a change in disease severity; extrapyradimal symptoms and weight gain as side effects; and a reduction in suicide (for clozapine only). Intervention costs included treatment cost, hospitalization cost as well as time and travel cost of patients and families. Uncertainty was evaluated using multivariate Monte Carlo simulation. As a generic version of risperidone is expected on the market soon, a sensitivity analysis of varying costs of risperidone was undertaken. RESULTS: The cost-effectiveness results indicate generic risperidone, assuming a cost of 4 baht per 2-mg tablet will improve health outcomes and save costs if replacing the currently predominant treatment of typical drugs. The ideal combination of treatments is risperidone as fi rst line treatment (dominant intervention), adding family interventions for all patients (Incremental cost-effectiveness ratio of 2000 baht/ DALY) and adding clozapine to severe patients (an estimated 33% of patients). This addition has an incremental cost-effectiveness ratio of 290,000 baht/DALY, which is still less than three times GDP per capita. CONCLUSIONS: The introduction of generic risperidone will lead to more effi cient outcomes and lower costs if it can be produced for less than 10 baht per 2-mg tablet. Providing family interventions for all patients and treating more severe patients with clozapine can further improve outcomes of Thai patients with schizophrenia in a cost-effective manner. OBJECTIVES: Adequate duration of antidepressant therapy is essential for the treatment of major depressive disorder (MDD). This study examined the association between medication persistence and hospitalization and emergency room (ER) visit for high-cost patients with MDD in the usual clinical setting. METHODS: In a large US commercial managed-care claims database, 8177 MDD patients (18 to 64 years old) were initiated on duloxetine or venlafaxine XR during the calendar year 2006. All of the patients had no active prescription of study medications for 6 months prior to initiation and had continuous enrollment for 12 months prior to and postmedication initiation. High-cost patients were defi ned as patients whose total treatment costs in the prior 1 year were above the median of total costs for all MDD patients in 2005 (n = 5093). After propensity-score matching on observed variables known to affect medication choices, 1714 duloxetine patients and an equal number of venlafaxine XR patients were included for this analysis. Medication persistence was defi ned as the length of therapy without exceeding a 15-day gap. Logistic regression analyses were used to examine the associations between medication persistence and health-care utilization in the year following treatment initiation. RESULTS: In the post 1 year, duloxetine patients stayed on the medication signifi cantly longer (119.5 vs. 110.4 days, P = 0.047) than venlafaxine XR patients. Treatment persistence >3 months was signifi cantly associated with reduced odds of psychiatric hospitalization (OR = 0.46, 95% CI = 0.37-0.58), nonpsychiatric hospitalization (OR = 0.77, 95% CI = 0.64-0.92), and ER visit (OR = 0.69, 95% CI = 0.60-0.79). Treatment differences in health-care utilization were not statistically signifi cant. These fi ndings had no essential changes with adjustment for demographics, comorbid conditions, and prior health-care utilization and separate analyses for duloxetine and venlafaxine XR patients. CONCLUSIONS: Duloxetine therapy appears to have longer persistence than venlafaxine XR for high-cost patients with MDD. Medication persistence >3 months is associated with reduced hospitalization and ER visit. OBJECTIVES: Adherence and persistence to prescribed medication is important in the management of major depressive disorder (MDD). This study compared adherence and persistence between duloxetine and escitalopram among high health-care utilizers with MDD. METHODS: In a large US commercial managed-care claims database, 10,803 MDD patients (18 to 64 years) who initiated on duloxetine (n = 4542) or escitalopram (n = 6261) during the calendar year 2006 were identifi ed. All of the patients had no recorded prescription of study medications for 6 months prior to initiation and had continuous enrollment for 12 months prior to and post-medication initiation. High health-care utilizers (duloxetine, n = 3113; escitalopram, n = 3157) were defi ned as patients whose total treatment costs in the prior 1 year were above the median of total costs for all MDD patients in 2005. Adherence was defi ned as Medication Possession Ratio (MPR) ≥0.8, and persistence was defi ned as the length of therapy without exceeding a 30-day gap. Statistical analyses included chi-square test, Wilcoxon rank sum test, multivariate logistic and Cox regression. RESULTS: In the post 6 months (6M) and 12 months (12M), adherence rates were signifi cantly higher for duloxetine-treated patients (6M 54.6% and 12M 40.9%) than escitalopram-treated patients (6M 47.4% and 12M 31.7%) (P-values < 0.001). Duloxetinetreated patients also stayed on the medication signifi cantly longer (6M 115.9 days and 12M 171.1 days) than escitalopram-treated patients (6M 108.4 days and 12M 154.6 days) (P-values < 0.001). Results were essentially unchanged with adjustment for demographics, comorbid conditions, prior medications use, and health-care utilization, resulting in duloxetine therapy maintaining its better adherence and longer persistence versus escitalopram. CONCLUSIONS: Duloxetine-treated patients appear to be more adherent and have a longer stay on the medication than escitalopramtreated patients for high resources utilizers. Further research is needed to examine clinical and economic benefi ts of better adherence and persistence with duloxetine therapy. OBJECTIVES: Treatment discontinuation is an important effectiveness measure for evaluating antipsychotic treatment, yet is typically assessed only on a high level (e.g., "lack of effi cacy," "adverse event," or "patient decision"). The RAD-I was developed as a structured interview assessing patient's perspective regarding specifi c reasons for antipsychotic discontinuation and continuation and the RAD-Q as a questionnaire assessing clinician's perspective. This study assessed the validity of the RAD measures in a randomized clinical trial. METHODS: The RAD was assessed at baseline (referring to medications prior to the trial) and endpoint (referring to discontinuation/ continuation of study drug) in a 12-week schizophrenia clinical trial. To assess its psychometric properties, we examined content validity, discriminate validity, and agreement between RAD scales using endpoint data (N = 158). RESULTS: Of 29 potential primary reasons for medication discontinuation, the most common was insuffi cient improvement/worsening of positive symptoms (24%) followed by adverse events (22%). A high level of concurrent validity was observed, as 89% of patients discontinuing medication due to "lack of effi cacy" (87%, "adverse events") per the standard trial form had lack of effi cacy ("adverse events") as a primary or very important reason on the RAD. Patients indicating lack of improvement/worsening of positive symptoms as a primary reason for medication discontinuation on the RAD had signifi cantly less improvement in PANSS positive score than patients not reporting this as a reason. Similar results were observed for the RAD mood items (per MADRS) and functional status (per QLS) as well as for corresponding analyses assessing reasons for continuation. Agreement between the clinician and patient scores was high (range 73% to 100%). CONCLUSIONS: This initial psychometric assessment suggests the RAD is a valid tool for gathering detailed information regarding reasons for antipsy-
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University of Queensland, Brisbane, QLD, Australia, 2 The University of Queensland, Brisbane, Queensland, Australia OBJECTIVES: To determine the cost-effectiveness of interventions for major depression in Thailand. METHODS: A microsimulation model was developed to describe the course of disease in individuals. Model inputs included Thai data on disease parameters and costs while impact measures are derived from a systematic review and meta-analysis of the international literature. Results are presented as cost (Thai Baht) per disability adjusted life-year (DALY) averted, compared to the null scenario (do nothing). Fluoxetine as the cheapest antidepressant drug in Thailand was analyzed for treatment of episodes plus a 6 month continuation phase and for maintenance treatment over 5 years of follow-up. Cognitive behavioral therapy (CBT) was analyzed for episodic treatment and for 5-year maintenance treatment. RESULTS: The incremental cost-effectiveness ratios (ICER) of fl uoxetine for episodic treatment with or without a continuation or maintenance phase are just below one times GDP per capita in Thailand of 110,000 Baht. CBT during an episode of depression (ICER = 39,000) is more costeffective than medications (ICER = 88,000); a maintenance version of CBT is the most cost-effective option with an ICER of 27,000. Episodic drug treatment has the lowest cost (250 Million Baht) and averts 3000 DALYs. Episodic treatment with CBT, which has an ongoing effect for 1.5 years, costs 100 Million Baht more than drug treatment but it averts more than 6000 DALYs compared to drugs. CONCLUSIONS: CBT is the most cost-effective treatment option for both episodic and maintenance treatment. Maintenance treatment is the more cost-effective of the two. However, there is currently a lack of mental health personal, especially psychiatrists and psychologists, who would be expected to deliver CBT in Thailand. Antidepressant drugs are quite a bit less effective but also less costly than CBT.
PMH12

COST-EFFECTIVENESS OF TYPICALS, ATYPICALS AND PSYCHOSOCIAL INTERVENTIONS FOR SCHIZOPHRENIA IN THAILAND
Phanthunane P 1 , Vos T 2 , Whiteford H 1 , Bertram M 2 1 University of Queensland, Brisbane, QLD, Australia; 2 The University of Queensland, Brisbane, Queensland, Australia OBJECTIVES: To determine the optimal treatment package, including drug and non drug interventions, for schizophrenia in Thailand. METHODS: A Markov model was used to evaluate the cost-effectiveness of typical antipsychotics, generic risperidone, olanzapine, clozapine and family interventions. Health outcomes were measured in disability adjusted life-years. We considered health outcomes from a change in disease severity; extrapyradimal symptoms and weight gain as side effects; and a reduction in suicide (for clozapine only). Intervention costs included treatment cost, hospitalization cost as well as time and travel cost of patients and families. Uncertainty was evaluated using multivariate Monte Carlo simulation. As a generic version of risperidone is expected on the market soon, a sensitivity analysis of varying costs of risperidone was undertaken. RESULTS: The cost-effectiveness results indicate generic risperidone, assuming a cost of 4 baht per 2-mg tablet will improve health outcomes and save costs if replacing the currently predominant treatment of typical drugs. The ideal combination of treatments is risperidone as fi rst line treatment (dominant intervention), adding family interventions for all patients (Incremental cost-effectiveness ratio of 2000 baht/ DALY) and adding clozapine to severe patients (an estimated 33% of patients). This addition has an incremental cost-effectiveness ratio of 290,000 baht/DALY, which is still less than three times GDP per capita. CONCLUSIONS: The introduction of generic risperidone will lead to more effi cient outcomes and lower costs if it can be produced for less than 10 baht per 2-mg tablet. Providing family interventions for all patients and treating more severe patients with clozapine can further improve outcomes of Thai patients with schizophrenia in a cost-effective manner.
MENTAL HEALTH -Patient-Reported Outcomes Studies
PMH13 ASSOCIATION OF MEDICATION PERSISTENCE AND HEALTH-CARE UTILIZATION IN HIGH-COST PATIENTS WITH MAJOR DEPRESSIVE DISORDER TREATED WITH DULOXETINE OR VENLAFAXINE XR
Liu X 1 , Tepper P 2 , Mullins CD 3 , Faries D 1 , Johnstone B 1 1 Eli Lilly and Company, Indianapolis, IN, USA; 2 University of Pittsburgh, Pittsburgh, PA, USA; 3 University of Maryland School of Pharmacy, Baltimore, MD, USA OBJECTIVES: Adequate duration of antidepressant therapy is essential for the treatment of major depressive disorder (MDD). This study examined the association between medication persistence and hospitalization and emergency room (ER) visit for high-cost patients with MDD in the usual clinical setting. METHODS: In a large US commercial managed-care claims database, 8177 MDD patients (18 to 64 years old) were initiated on duloxetine or venlafaxine XR during the calendar year 2006. All of the patients had no active prescription of study medications for 6 months prior to initiation and had continuous enrollment for 12 months prior to and postmedication initiation. High-cost patients were defi ned as patients whose total treatment costs in the prior 1 year were above the median of total costs for all MDD patients in 2005 (n = 5093). After propensity-score matching on observed variables known to affect medication choices, 1714 duloxetine patients and an equal number of venlafaxine XR patients were included for this analysis. Medication persistence was defi ned as the length of therapy without exceeding a 15-day gap. Logistic regression analyses were used to examine the associations between medication persistence and health-care utilization in the year following treatment initiation. RESULTS: In the post 1 year, duloxetine patients stayed on the medication signifi cantly longer (119.5 vs. 110.4 days, P = 0.047) than venlafaxine XR patients. Treatment persistence >3 months was signifi cantly associated with reduced odds of psychiatric hospitalization (OR = 0.46, 95% CI = 0.37-0.58), nonpsychiatric hospitalization (OR = 0.77, 95% CI = 0.64-0.92), and ER visit (OR = 0.69, 95% CI = 0.60-0.79). Treatment differences in health-care utilization were not statistically signifi cant. These fi ndings had no essential changes with adjustment for demographics, comorbid conditions, and prior health-care utilization and separate analyses for duloxetine and venlafaxine XR patients. CONCLUSIONS: Duloxetine therapy appears to have longer persistence than venlafaxine XR for high-cost patients with MDD. Medication persistence >3 months is associated with reduced hospitalization and ER visit.
PMH14 ADHERENCE AND PERSISTENCE WITH DULOXETINE VERSUS ESCITALOPRAM AMONG HIGH HEALTH-CARE RESOURCES UTILIZERS WITH MAJOR DEPRESSIVE DISORDER
Tepper P 1 , Liu X 2 , Able SL 2 , Johnstone B 2 1 University of Pittsburgh, Pittsburgh, PA, USA; 2 Eli Lilly and Company, Indianapolis, IN, USA OBJECTIVES: Adherence and persistence to prescribed medication is important in the management of major depressive disorder (MDD). This study compared adherence and persistence between duloxetine and escitalopram among high health-care utilizers with MDD. METHODS: In a large US commercial managed-care claims database, 10,803 MDD patients (18 to 64 years) who initiated on duloxetine (n = 4542) or escitalopram (n = 6261) during the calendar year 2006 were identifi ed. All of the patients had no recorded prescription of study medications for 6 months prior to initiation and had continuous enrollment for 12 months prior to and post-medication initiation. High health-care utilizers (duloxetine, n = 3113; escitalopram, n = 3157) were defi ned as patients whose total treatment costs in the prior 1 year were above the median of total costs for all MDD patients in 2005. Adherence was defi ned as Medication Possession Ratio (MPR) ≥0.8, and persistence was defi ned as the length of therapy without exceeding a 30-day gap. Statistical analyses included chi-square test, Wilcoxon rank sum test, multivariate logistic and Cox regression. RESULTS: In the post 6 months (6M) and 12 months (12M), adherence rates were signifi cantly higher for duloxetine-treated patients (6M 54.6% and 12M 40.9%) than escitalopram-treated patients (6M 47.4% and 12M 31.7%) (P-values < 0.001). Duloxetinetreated patients also stayed on the medication signifi cantly longer (6M 115.9 days and 12M 171.1 days) than escitalopram-treated patients (6M 108.4 days and 12M 154.6 days) (P-values < 0.001). Results were essentially unchanged with adjustment for demographics, comorbid conditions, prior medications use, and health-care utilization, resulting in duloxetine therapy maintaining its better adherence and longer persistence versus escitalopram. CONCLUSIONS: Duloxetine-treated patients appear to be more adherent and have a longer stay on the medication than escitalopramtreated patients for high resources utilizers. Further research is needed to examine clinical and economic benefi ts of better adherence and persistence with duloxetine therapy.
PMH15 THE VALIDATION OF TWO MEASURES ASSESSING REASONS FOR ANTIPSYCHOTIC DISCONTINUATION AND CONTINUATION FROM PATIENTS' AND CLINICIANS' PERSPECTIVES
Faries D, Ascher-Svanum H, Nyhuis A, Anderson J, Phillips G Eli Lilly and Company, Indianapolis, IN, USA OBJECTIVES: Treatment discontinuation is an important effectiveness measure for evaluating antipsychotic treatment, yet is typically assessed only on a high level (e.g., "lack of effi cacy," "adverse event," or "patient decision"). The RAD-I was developed as a structured interview assessing patient's perspective regarding specifi c reasons for antipsychotic discontinuation and continuation and the RAD-Q as a questionnaire assessing clinician's perspective. This study assessed the validity of the RAD measures in a randomized clinical trial. METHODS: The RAD was assessed at baseline (referring to medications prior to the trial) and endpoint (referring to discontinuation/ continuation of study drug) in a 12-week schizophrenia clinical trial. To assess its psychometric properties, we examined content validity, discriminate validity, and agreement between RAD scales using endpoint data (N = 158). RESULTS: Of 29 potential primary reasons for medication discontinuation, the most common was insuffi cient improvement/worsening of positive symptoms (24%) followed by adverse events (22%). A high level of concurrent validity was observed, as 89% of patients discontinuing medication due to "lack of effi cacy" (87%, "adverse events") per the standard trial form had lack of effi cacy ("adverse events") as a primary or very important reason on the RAD. Patients indicating lack of improvement/worsening of positive symptoms as a primary reason for medication discontinuation on the RAD had signifi cantly less improvement in PANSS positive score than patients not reporting this as a reason. Similar results were observed for the RAD mood items (per MADRS) and functional status (per QLS) as well as for corresponding analyses assessing reasons for continuation. Agreement between the clinician and patient scores was high (range 73% to 100%). CONCLUSIONS: This initial psychometric assessment suggests the RAD is a valid tool for gathering detailed information regarding reasons for antipsy-chotic discontinuation and continuation from patients' and clinicians' perspectives. Further information is needed about the psychometric properties in usual care settings.
PMH16
PHARMACIST-RUN METHADONE CLINIC IN A MALAYSIAN PUBLIC HEALTH CENTER: EVALUATING PATIENT SATISFACTION AND QUALITY OF LIFE OUTCOMES
Chiew GP 1 , Shafi e AA 2 , Hassali MA 2 , Awaisu A 2 , Cheah WK 3 1 Larut Matang & Selama Health Offi ce, Taiping, Perak, Malaysia; 2 Universiti Sains Malaysia, Minden, Penang, Malaysia; 3 Hospital Taiping, Taiping, Malaysia OBJECTIVES: To assess the satisfaction and health-related quality of life (HRQoL) improvement of patients enrolled in a pharmacist-run Methadone Maintenance Therapy (MMT) program. METHODS: A cohort study design was used to measure satisfaction and to evaluate changes in HRQoL of patients after one month of receiving methadone treatment at Taiping Health Clinic. Respondent's satisfaction was measured by using an eight-item pre-validated questionnaire. A post-survey reliability analysis of the questionnaire showed a high internal consistency of the items (Cronbach's α = 0.785). Meanwhile, the HRQoL was measured using a validated EQ-5D and EQ-VAS questionnaire that are administered by face-to-face interview in two phases, after 1 month interval. The data were analyzed by using both descriptive statistics (frequencies and percentages) and inferential statistics (χ 2 test, paired t-test and the McNemar χ 2 test). RESULTS: All 54 patients in MMT clinic participated, but only 40 (74.1%) completed this study. Average methadone dose in both phases were low (Phase One = 37.4 mg [SD = 22.2], Phase Two = 44.4 mg [SD = 21.3]) that caused majority of respondents wishing to increase their current dose. Respondents were not satisfi ed with needs to come clinic daily (n = 18, 33.4%) and did not believe that MMT clinic can help in cessation of drug abuse (n = 9, 16.7%). These two items were signifi cantly associated with travelling distance of respondents to clinic (P = 0.001 and P = 0.039, respectively). Only pain/discomfort domain of the EQ-5D showed a signifi cant improvement from the baseline (P = 0.035). EQ-VAS score signifi cantly improved from 64.69 (SD = 16.7) at baseline to 71.43 (SD = 14.9) during the 1-month follow-up (P = 0.008). CONCLUSIONS: MMT program was able to improve patients' QoL even in short duration of time. Improvement on dissatisfactions toward travelling distance, needs to travel daily to clinic and inadequate dose will help to increase treatment success.
PMH17
COMPARISON OF HRQOL BETWEEN PATIENT RECEIVING METHADONE MAINTENANCE THERAPY (MMT) AND REHABILITATION PROGRAM
Abdul Ghani N, Shafi e AA, Hassali MA Universiti Sains Malaysia, Minden, Penang, Malaysia OBJECTIVES: This study aims to compare the HRQoL between patients receiving methadone maintenance therapy (MMT) program with those in the rehabilitation program. METHODS: This was a cross-sectional study involving 400 randomly selected patients from two primary and secondary hospitals and one rehabilitation center (PUSPEN) in northern part of Malaysia. Consented patient was interviewed to collect their socio-demography, drug consumption and quality of life information. The quality of life was measured by using EQ-5D and EQ-VAS questionnaires. Their quality of life scores were then compared using independent t-test. RESULTS: Majority of the participants were male with mean age 38.49 (SD = 9.6) in MMT group and 34.77 (SD = 8.6) in rehabilitation group. Mean duration of treatment for MMT group was 17.5 months (SD = 15.74) and rehabilitation group was 7.8 months (SD = 3.52). EQ-5D score was signifi cantly (P = 0.01) higher among MMT participants (mean = 0.783, SD = 0.190) compared to those in rehabilitation program (mean = 0.707, SD = 0.227). Participants receiving MMT treatment also had lesser problems in mobility (10.5% vs. 21%; P < 0.01), normal activity (6.5% vs. 15%; P < 0.05) and anxiety (54.5% vs. 71%; P < 0.001). There was no statistically difference found between the groups in self care activity and pain dimensions. However, EQ-VAS score was significantly lower in MMT group compared to rehabilitation group (65.5 [SD = 17.9] vs. 73.5 [SD = 17.6], P < 0.001). CONCLUSIONS: This study shows that treatment for patient with substance use disorder with MMT program can provide a better quality of life compared to rehabilitation program (PUSPEN). Variation seen between EQ-5D and EQ-VAS scores suggest that patients might perceived their health worst than the general population value.
PMH18 THE EFFECT OF DIAGNOSED, SELF-REPORTED, AND AT-RISK DEPRESSION ON HEALTH-RELATED QUALITY OF LIFE AND WORK PRODUCTIVITY IN JAPAN AND EUROPE
DiBonaventura MD 1 , Fukuda T 2 , Nagae T 3 , Wagner JS 1 , Stankus A 4 1 Kantar Health, New York, NY, USA; 2 Tokyo University, Tokyo, Japan; 3 York Pharma KK, Tokyo, Japan; 4 Kantar Health, Princeton, NJ, USA OBJECTIVES: The aim of the current study was to establish the burden of depression (diagnosed, self-reported, and at-risk) in both Europe and Japan. METHODS: Data from the 2008 EU and 2008 Japan National Health and Wellness Survey (NHWS) were used. Patients were categorized into four groups: diagnosed depression, selfreported depression, at-risk for depression, and controls. Differences among these groups were examined on quality of life (mental (MCS) and physical component summary (PCS) scores of the SF-12v2), as well as overall work impairment, controlling for demographics and patient characteristics. RESULTS: In the EU, 5848 patients (10.9%) were diagnosed, 2037 (3.8%) were self-reported, 13,168 (24.6%) were at-risk, and 32,471 (60.7%) were controls. In Japan, 884 (4.4%) were diagnosed, 162 (0.8%) were self-reported, 5681 (28.4%) were at-risk, and 13,273 (66.4%) were controls. After controlling for demographics and patient characteristics, those with diagnosed depression (Adjusted Mean [Madj] = 34.4), self-reported depression (M-adj = 35.5), and at-risk depression (M-adj = 41.0) reported signifi cantly lower levels of MCS scores than controls ((M-adj = 51.10, P's < 0.0001) across all countries. The gap between controls and self-reported depression (b = 3.18, P < 0.0001) and at-risk depression (b = 0.63, P < 0.001) was signifi cantly greater in Japan than in the EU. Both those with diagnosed (Madj = 46.2) and at-risk (M-adj = 49.4) depression reported signifi cantly lower levels of PCS than controls (M-adj = 49.6, P's < 0.05). Finally, those diagnosed with depression (M-adj = 39.2%), self-reported depression (M-adj = 30.9%), and at-risk for depression (M-adj = 23.3%) all reported signifi cantly more overall work impairment than controls (M-adj = 12.8%). There was also a signifi cant interaction, such that the difference in impairment between patients diagnosed with depression and controls was signifi cantly greater in Japan (P < 0.05). CONCLUSIONS: Levels of diagnosed and self-reported depression were lower in Japan than in Europe, yet rates of at-risk depression were higher. Although the burden of depression was substantial, the results suggest that the work impairment burden in Japan is signifi cantly greater than in the EU. Patients were categorized into four groups: diagnosed depression, self-reported depression, at-risk for depression, and controls. Differences among these groups were examined on quality of life (mental (MCS) and physical component summary (PCS) scores of the SF-12v2), as well as overall work impairment, controlling for demographics and patient characteristics. RESULTS: In the EU, 5848 patients (10.9%) were diagnosed, 2037 (3.8%) were self-reported, 13168 (24.6%) were at-risk, and 32471 (60.7%) were controls. In China, 339 (2.5%) were diagnosed, 348 (2.6%) were self-reported, 3883 (29.2%) were at-risk, and 8752 (65.7%) were controls. Adjusting for demographics and comorbidities, those with diagnosed (b = −16.00, P < 0.0001) and self-reported (b = −14.42, P < 0.0001) depression, and those at-risk for depression (b = −9.22, P < 0.0001) reported signifi cantly lower MCS than controls. Those diagnosed (b = −3.62, P < 0.0001) and at-risk (b = −0.47, P = 0.0022) for depression reported signifi cantly lower PCS than controls. In addition, the MCS difference between those with diagnosed, self-reported, or at-risk depression relative to controls was signifi cantly greater in Europe than in China (b = 5.88, P < 0.0001; b = 5.60, P < 0.0001; b = 3.49, P < 0.0001, respectively). However, the PCS gap between patients at-risk for depression and controls was signifi cantly greater in China than in Europe (b = −0.99, P < 0.0001). Finally, the work impairment gap between patients with diagnosed, self-reported, or at-risk depression and controls was significantly greater in Europe than in China (b = −0.35, P = 0.0002; b = −0.40, P < 0.0001; b = −0.08, P = 0.0455, respectively). CONCLUSIONS: Depression was associated with a substantial burden on patients. The impact of depression on mental quality of life and work impairment was greatest in Europe while the impact of depression on physical quality of life was greatest in China.
MENTAL HEALTH -Health Care Use & Policy Studies
PMH20 SWITCHING BETWEEN SSRI BRANDS IN AUSTRALIA
Ortiz MS 1 , Calcino G 2 1 University of NSW, Darlinghurst, NSW, Australia; 2 HI Connections, Canberra, ACT, Australia OBJECTIVES: To study the extent of brand substitution and switching between Selective Serotonin Reuptake Inhibitors (SSRI) available on the Pharmaceutical Benefi t Scheme (PBS). METHODS: PBS prescription claims data provided by Medicare Australia of a 10% random sample of all Australian long-term concession card holders covering the time period August 2007 through July 2008 were assessed. Patients had to fi ll at least four prescriptions for an SSRI with generics over the 1-year period (fl uoxetine [2 doses forms with up to 12 brands], fl uvoxamine [2 strengths with up to 5 brands], paroxetine [1 strength with 11 brands] and sertraline [2 strengths with up to 13 brands]). The proportions of non-switchers (single brand only) and multiple switchers (two or more switches between brands) were determined for each strength of each SSRI molecule. RESULTS: A total of 18,691 Concessional patients fi lled at least four prescriptions for a SSRI in the 12-month time window. The majority of these patients received a single brand over the period: ranging from 49% for fl uvoxamine to 67% for fl uoxetine. Only a small proportion received three or more brands: ranging from 12% for fl uoxetine to 16% for fl uvoxamine. The proportions of multiple switchers varied slightly between molecules with: 22% for fl uoxetine, 32% for fl uvoxamine, 26% for paroxetine and 24% for sertraline. Switching was greater for
